Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005) - LeWitt, P A; Guttman, M; Tetrud, J W (Ann Neurol, 2008)
et al.